Transdermal Nicotine Treatment and Progression of Early Parkinson's Disease

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in the context of parkinson's disease in this randomized controlled trial publication.

BACKGROUND: Epidemiologic studies show that smokers have a lower incidence of Parkinson’s disease.

Nicotine has been hypothesized to slow progression in early Parkinson’s disease.

Who Took Part

The abstract describes 163 participants taking part.

RESULTS: Among 163 participants, 101 were assessed for the primary end point.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Therapeutic nicotine (patch, non-peptide), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.

More than one site took part, so the participants came from several places.

What Was Measured

METHODS: In a double-blind, placebo-controlled multicenter trial, the researchers randomly assigned patients with Parkinson’s disease, diagnosed within 18 months, who were in Hoehn and Yahr disease stage less than or equal to 2 (range from 0 to 5; higher scores indicate greater impairment), who were therapy naïve (except for stable monoamine-oxidase-B inhibition), and not requiring dopaminergic therapy, to transdermal nicotine or placebo.

The primary end point was change in Unified Parkinson’s Disease Rating Scale parts I–III (Total UPDRS) score (range from 0 to 172; higher scores indicate greater impairment) between baseline and 60 weeks (52 weeks of trial therapy, 8 weeks of washout).

PubMed files the paper under topics including Parkinson Disease, Antiparkinson Agents, Nicotine, Dopamine and Administration, Cutaneous.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 163 participants in people with parkinson's disease.

The publication is from 2023 (NEJM evidence), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, Parkinson's disease research.